Wall Street analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce earnings of ($0.58) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.56). Dynavax Technologies posted earnings per share of ($0.38) during the same quarter last year, which indicates a negative year over year growth rate of 52.6%. The business is expected to issue its next earnings report on Friday, November 2nd.

On average, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current year, with EPS estimates ranging from ($2.42) to ($2.33). For the next fiscal year, analysts expect that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The company had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $1.88 million. Dynavax Technologies had a negative return on equity of 72.31% and a negative net margin of 8,570.06%. The business’s quarterly revenue was up 1094.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.41) EPS.

Several research firms recently weighed in on DVAX. Cantor Fitzgerald restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research note on Monday, August 6th. ValuEngine downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. BidaskClub downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, June 8th. Finally, Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $27.50.

Several institutional investors have recently bought and sold shares of DVAX. Tiverton Asset Management LLC purchased a new stake in Dynavax Technologies during the 2nd quarter valued at $184,000. WINTON GROUP Ltd purchased a new stake in Dynavax Technologies during the 1st quarter valued at $199,000. Xact Kapitalforvaltning AB purchased a new stake in Dynavax Technologies during the 1st quarter valued at $200,000. Commonwealth Equity Services LLC purchased a new stake in Dynavax Technologies during the 1st quarter valued at $212,000. Finally, Bank of Montreal Can boosted its stake in Dynavax Technologies by 365.4% during the 2nd quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 10,943 shares during the last quarter. Institutional investors own 82.02% of the company’s stock.

Shares of Dynavax Technologies stock traded down $0.30 during midday trading on Thursday, hitting $12.10. The company had a trading volume of 585,800 shares, compared to its average volume of 1,358,197. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $776.43 million, a P/E ratio of -7.08 and a beta of 0.24. Dynavax Technologies has a 52-week low of $11.35 and a 52-week high of $24.45.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

See Also: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.